Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 24;6:107. doi: 10.1038/s41541-021-00365-w

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — a Gene map in pETDuet-1 for expression of a mosaic mCuMV_TT-MERS vaccine candidate based on self-assembling of unmodified (CuMV_TT) and genetically modified monomers displaying RBM (CuMV_TT-RBM). b Agarose gel analysis of sucrose gradient fractions, Lane 1: molecular marker, Lanes 2–7: 60 – 0 sucrose gradient fractions of mCuMV_TT-MERS. Fractions 40% and 50% contain VLPs, incorporated host cell ssRNA is stained with ethidium bromide. c SDS-PAGE stained with coomassie blue stain, Lane 1: protein marker, Lanes 2–4: mCuMV_TT-MERS vaccine showing a band of unmodified CuMV_TT monomer of ~ 28 kDa and RBM antigen-containing CuMV_TT monomer of ~ 42 kDa (2, 4, and 8 µg of protein loaded). d SDS-PAGE stained with coomassie blue stain showing the stability of mCuMV_TT-MERS vaccine after 1 month in RT, Lane 1: protein marker, Lane 2: mCuMV_TT-MERS vaccine. e 3D model of mCuMV_TT-MERS vaccine illustrating unmodified CuMV_TT monomer (in gray color) and the genetically modified CuMV_TT monomer (in blue color) displaying RBM (in pink color) and a video (Supplementary Data). f Dynamic light scattering. g Electron microscopy (EM) of mCuMV_TT-MERS vaccine, scale 200 nm.